Immediate Impact

5 from Science/Nature 72 standout
Sub-graph 1 of 22

Citing Papers

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
2021 Standout
2 intermediate papers

Works of John T. Kenny being referenced

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine
1993

Author Peers

Author Last Decade Papers Cites
John T. Kenny 559 406 60 165 26 1.1k
Ingrid Aasen 488 336 30 212 22 978
Margret S.H. Harris 546 401 15 95 20 909
Verity C. Leeson 795 564 23 165 44 1.3k
Adham Mancini‐Marïe 464 349 25 97 41 881
Douglas S. Lehrer 668 330 41 160 24 1.3k
Arielle D. Stanford 619 357 28 172 40 1.2k
R.C. Gur 541 546 23 93 17 1.1k
Gary Brucato 581 339 33 197 52 1.1k
Henning Witthaus 513 618 75 183 16 1.1k
Brian Kirkpatrick 549 244 62 95 11 893

All Works

Loading papers...

Rankless by CCL
2026